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                                             INTRODUCTION: 
 
               Rheumatoid arthritis is a chronic inflammatory and progressive disease 
characterized by various extra-articular manifestations. The presence of extra-articular 
manifestations of RA is associated with more severe disease, high rheumatoid factor 
levels and is considered a risk factor for early death in patients with rheumatoid arthritis. 
The presence of extra-articular manifestations may vary in different geographic areas and 
different ethnic groups. Extra- articular organ involvement includes skin, eyes, heart, 
lung, vasculitis, hematology etc. The presence of extra-articular manifestations is a major 
predictor of mortality in RA patients.(1) 
           This study focuses on the extra-articular manifestations in 100cases of rheumatoid  
arthritis  attending  outpatient department or admitted to ward at Coimbatore medical 
college hospital. 
 
 
  
``2 
 
AIM OF THE STUDY: 
 
 To investigate and compare the frequency and type of extra-articular manifestations 
 To correlate the number of extra-articular manifestations with the duration of the 
study 
In a well defined community based cohort of patients with rheumatoid arthritis 
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                                    RHEUMATOID ARTHRITIS: 
  Rheumatoid arthritis (RA) is a chronic, destructive, inflammatory arthropathy 
manifested by articular and extra-articular features. RA has profound effects on patient 
function and morbidity and exacts a substantial economic burden on the affected persons. 
 Although the pathology of the synovial inflammation and cartilage destruction 
that occurs in patients with RA has been described for decades, many important 
developments in the understanding of genetic influences and immune pathophysiologic 
mechanisms have recently been defined. (1) 
Basic research delineating the molecular mechanisms of synovial inflammation 
has driven the development of innovative therapies for patients with RA. Hopefully, new 
genomic and proteomic information will allow further stratification and identification of 
subsets of RA patients who respond better, longer, and with fewer adverse reactions to 
targeted therapies(1) 
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                                           PATHOGENESIS: 
Figure-1: Normal joint versus RA joint 
 
The pathology of RA involves a complex interaction of three different scientific 
domains:  
1) a complex genetic predisposition to the disease plus some environmental 
stimulus;  
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2) a self-perpetuating, self amplifying, intra-synovial immune response; and at the 
final stage, (2) 
3) Tissue injury mediated by pro-inflammatory cells, inflammatory effector 
molecules, and derivative enzymes.  
In individuals with RA, this process is orthotropic and produces a characteristic 
pathologic lesion in the synovium as well as the hallmark erosion of bone and destruction 
of cartilage at the joint margin.  
        The histopathology of RA synovium has been well described. The synovial lining, 
the interstitium, and the microvasculature are all involved. Early in the process, the 
synovial lining, which includes both Type A (macrophage-like) and Type B 
(mesenchymal or fibroblast-like) cells, becomes proliferative. The synovial lining 
increases in cell number and mass. Likewise, a diffuse and nodular inflammatory cell 
infiltrate is observed in the interstitium. It includes CD4+ and CD8+ lymphocytes, 
dendritic cells, and other antigen presenting cells. In some patients, the histologic 
appearance is quite dramatic, showing focal aggregation of both T- and B-cells, as well as 
the presence of germinal centers similar to that which is seen in lymphoid tissues. (2) 
         The synovium of the rheumatoid joint, although not malignant, often times behaves 
as a local invasive “tumor.” The microvasculature initially reveals endothelial cell 
activation. As the process matures, plasma cells and multinucleated giant cells appear, 
and the vascular supply becomes exuberant. Finally, the growing synovium appears as 
granulation tissue as it advances to the hyaline cartilage at the margin of the joint.(2) A 
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local effect of degradative enzymes and activated osteoclasts produces the classic erosion 
at the bone and cartilage margin. These enzymes may also affect structures that are more 
distant, including the tendons, ligaments, and other musculoskeletal structures. Erosions 
are produced by bone and matrix protein resorbing osteoclasts, which may be induced 
and activated by cytokines released into the inflammatory milieu.( 2) 
GENETICS AND ENVIRONMENTAL STIMULUS: 
                Genetic contributions for the pathogenesis of rheumatoid arthritis (RA) are very 
complex. Genetic studies in families of patients with RA suggest that monozygotic twins 
have a concordance rate for RA of between 15%-30%.  
                 Certain alleles of the HLA-DR4 locus were found to be associated with RA in 
Caucasian patients. Most scientific evidence now suggests that certain genes within the 
major histocompatibility complex (MHC), located on the short end of chromosome 6 
play the most significant role in the initiation of the rheumatoid disease .  
                  Evidence also suggests that there are RA susceptibility genes on other 
chromosomes that appear to correlate with the phenotypic presentation of RA. Recently, 
allelic variations in PTPN22, a gene that encodes a tyrosine kinase involved in inhibition 
of T-cell activation, have been shown to be associated with RA.   
                 Other factors are also involved in the triggering of RA in susceptible persons. 
One factor (not entirely extra genetic) is female sex. Particularly at younger ages of onset, 
RA is more common in women than in men, with a ratio of about 3:1. (2) 
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ROLE OF INNATE AND ADAPTIVE IMMUNITY: 
     A variety of genes and environmental factors contribute to susceptibility and 
pathogenesis of RA. The process of RA usually begins years before the onset of clinical 
features. This process usually involves breaking of tolerance and development of auto 
reactivity.  
       In the initial phases there is repeated activation of innate immunity. The innate 
immunity will activate fibroblast like synoviocytes, dendritic cells and macrophages in 
the initial phases in patients with hyperreactive immune system as evidenced by antibody 
production. 
      The individual genetic makeup including certain genetic polymorphisms and 
exposure to environmental factors both are needed. Chronic inflammation leads to protein 
citrullination at various sites including mucosal lining of lungs and joints.       
       Cigarette smoking bacterial products viral components can contribute to 
pathogenesis of RA.  
       Activation of innate immunity of synovial tissue causes increase in vascular leakage 
into the synovium production of chemo attractants that cause recruitment of immune cells 
into the joints and antigen processing by dendritic cells. (3)  
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Figure-2: Role of innate and adaptive immunity 
 
 
INTRA-SYNOVIAL IMMUNE RESPONSE: 
The synovium in RA is marked by hyperplasia of intimal lining and sublining 
infiltration with mononuclear cells, especially CD4+Tcells, macrophages and B cells. 
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Intimal lining display unusually aggressive features. Macrophages in the intimal lining 
are highly activated and produce many cytokines (3). Lymphocytes can either 
diffusely infiltrate the sub lining or form lymphoid aggregates with germinal 
centres.Sublining CD4+T cells mainly display the memory cell phenotype. Synovial B 
cells and plasma cells in RA exhibit evidence of antigen-driven maturation and 
production.Dendritic cells can present antigens to T cells in synovial germinal 
centres.Mast cells produce small molecule mediators of inflammation.Neutrophils are 
rarely present in RA synovial tissue but can be abundant in synovial tissues(4) 
Figure 3: Pathogenesis of RA: 
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EFFECTOR MOLECULES AND CARTILAGE DAMAGE: 
                 Pro inflammatory cytokines plays an important role in etiopathogenesis of 
rheumatoid arthritis. The T cell mediated macrophage stimulation leads on to the 
release IL-1 and TNF-alpha. These cytokines are found circulating in the serum, 
synovial fluid. Both of these cytokines have broad biologic effects, including the 
induction by synoviocytes of matrix metalloproteinases as well as the inhibition of 
tissue inhibitors of metalloproteinase (TIMPs)(4) 
                     In vivo and in vitro studies have documented that recombinant IL-1 and 
TNF-alpha injure normal hyaline cartilage. Chondrocytes, in particular, enter a 
catabolic phase when exposed to these cytokines, leading to an increase in 
collagenase production and a decrease in matrix protein synthesis (4).  
                    TNF-alpha also induces adhesion molecules, e.g., the intra-cellular adhesion 
molecule 1 (ICAM-1), which may in turn affect the homing and trafficking of 
inflammatory cells into the synovium.  
                     The “proof of concept” that TNF is an important mediator in the 
pathobiology of RA has been clearly shown by the profound clinical effects of the 
anti-TNF therapies (i.e., infliximab, etanercept, and adalimumab), on the signs, 
symptoms and structural damage that characterizes RA. Finally, the invasive 
nature of the RA pannus has suggested to some observers that the tissue behaves 
like a locally invasive tumor. 
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                     Indeed, growth factors such as TGF-alpha and FGF produced locally in the 
synovium by resident macrophages and fibroblasts may provide the drive for 
tissue expansion (4). 
Certain autoantibodies are associated with RA. The most characteristic, certainly 
from a historical perspective is rheumatoid factor (RF). The landmark discovery of RF 
which is present in approximately 75%-85% of people with RA, marked the beginning of 
the understanding that RA is a systemic autoimmine disease(5). Although it is relevant to 
the diagnosis of RA, RF may be of greater value to the clinician in prognosis.  
     Epidemiologic observations suggest that the presence of the RF is a marker that 
predicts more serious disease. Rheumatoid factors are auto reactive antibodies that bind 
to the Fc portion of IgG molecules. RF is not specific for rheumatoid arthritis, as it is 
observed in a host of other autoimmune disorders or infectious diseases. Also, by 
definition of how the test is performed, 5% of the normal population will have a positive 
test for RF.  
     RF of isotypes indicative of class switching (ie, IgG and IgA, rather than IgM) 
may be more specific, as are higher titers. Although the potential contribution of RF to 
the pathogenesis of RA is unclear, it has been suggested that RF may induce tissue 
damage by acting as immune complexes.  
     Over the years, a variety of other autoantibodies have been reported to be 
associated with RA, including antikeratin antibodies, antiperinuclear factor, and 
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antifilaggrin antibody (5). It has been demonstrated that the antigen recognized in 
common by these antibodies is citrullinated protein. 
    Citrulline is a nonstandard amino acid created by the deamination of arginine 
residues in proteins by the enzyme peptidyl arginine deiminase (PADI). Interestingly, in 
some populations, allelic variations in the genes encoding PADI have been shown to 
correlate with RA. 
     Tests for anti-CCP (cyclic citrullinated peptide) antibodies are as sensitive as 
RF for the diagnosis of RA and are more specific. Similarly, high titers of anti-CCP 
antibodies define patients with a more aggressive disease phenotype. 
 
EPIDEMIOLOGY: 
         RA occurs worldwide in virtually all ethnic groups, with a prevalence estimated   
between 0.5% and 1%.  
        It is significantly more common in females than in males . 
         Death often results from infection, heart disease, respiratory failure, renal failure, or 
gastrointestinal disease rather than from joint disease itself. Whether this is due to an 
inflammatory process or due to exposure to antirheumatic drugs or both is unclear.(6)  
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CLINICAL FEATURES: Table:1 -ACR/EULAR classification criteria for RA:
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Joint Manifestations: 
          Morning gel describes a peculiar stiffness that is pronounced in the morning or 
after periods of inactivity. It plagues most patients with active inflammatory arthritis, 
including those with RA. Its duration and quality often times provide the clues to early 
diagnosis of an inflammatory arthropathy.  
           The clinical hallmark of RA is a symmetrical polyarthritis involving the proximal 
interphalangeal joints (PIPs), metacarpophalangeal joints (MCPs), wrists, elbows, 
shoulders, hips, knees, ankles, and metatarsophalangeal joints (MTPs).  
            The hands and wrists are affected in approximately 90% of RA patients. Early in 
RA, joint tenderness and subtle swelling are observed, but after months to years the 
synovitis becomes proliferative and destructive.  
             The tissue within the joint becomes boggy to the touch, then typical joint 
deformities appear, including ulnar drift at the MCPs, rotatory subluxation at the wrist 
(ulnar styloid), and the “swan-neck” (flexion of DIP, hyperextension of PIP) and 
“boutonniere” (hyperextension of DIP, flexion of PIP) deformities. Most studies 
involving an inception cohort of patients suggest an overall, relatively linear rate of joint 
damage progression. 
             The development of erosions correlates with the persistence of inflammation, as 
evidenced by clinical measures of morning stiffness, synovial swelling, and elevation of 
erythrocyte sedimentation rate and other acute phase reactants. 
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             Magnetic resonance imaging (MRI) visualizes and quantifies tissue or “synovial 
load” and also detects early invasion of pannus into hyaline cartilage and sub-chondral 
bone. There is also increasing interest in the use of ultrasonography, which can visualize 
bony erosions, joint fluid, and synovial hypertrophy.(7) 
Figure 4: Articular manifestations of RA: 
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A syndrome of “pseudo-thrombophlebitis” can be seen in RA patients with active 
synovitis of the knee. Typically, a swollen, warm, tender calf causes problems with 
weight bearing, and the physical examination findings clearly mimic that of deep venous 
thrombophlebitis. (7) 
SPINAL INVOLVEMENT:           
       The cervical spine is a common site of involvement in RA. In autopsy studies, up to 
50% of patients with RA show some cervical spine involvement. There is a direct 
relationship between cervical spine disease and the presence of erosive peripheral joint 
disease.  
          Proliferative synovitis can damage the ligaments and articular cartilage of the 
cervical spine, causing several types of cervical spine instability. These include:  
              1) atlantoaxial subluxation in 50%-70% of patients;  
              2) subaxial subluxation in 20%-25% of patients; and  
               3) basilar invagination into the foramen magnum alone or in combination with 
atlantoaxial subluxation in approximately 20% of patients.  
    Symptoms of cervical spine involvement in RA include neck pain, occipital headache, 
and paresthesias in the extremities. (8) 
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   Figure-5: 
    
 
FIGURE: 5 
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Pleuropulmonary manifestations: 
       Abnormalities of the pleura and lungs have been detected by high-resolution  
omputed tomography (HRCT) in up to 75% of patients with RA. However, pleura 
inflammation is often asymptomatic and may not be detected until chest radiographs are 
done for other reasons. The prevalence of pleural effusion in RA is only about 5%. In 
some patients the pleural fluid glucose may be dramatically low compared to serum 
levels. Although it may present rarely before arthritis is manifested, pleural effusion 
usually occurs in individuals with active established RA. About one-third of patients with 
RA with pleural effusions have coexisting interstitial lung disease.(8) 
Interstitial pulmonary fibrosis occurs in 20%-40% of patients with RA, more 
commonly in patients with rheumatoid nodules and serum rheumatoid factor. It can be 
asymptomatic in its early stages because the decreased physical activity of patients with 
RA may be insufficient to induce dyspnea. The early radiographic changes of interstitial 
pulmonary fibrosis, consisting of ground-glass opacities predominantly in the lower 
lungs, may not be evident on conventional plain radiographs but appear as high-
attenuation lesions at the periphery of the lungs on HRCT. Compared to HRCT, 
pulmonary function testing, especially assessment of residual volume, is a more sensitive 
but relatively nonspecific indicator of interstitial pulmonary fibrosis in RA. Interstitial 
lung disease in patients with RA may also be a complication of gold or methotrexate 
therapy, and there have also been anecdotal reports associated with the TNF inhibitors.(8) 
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              Because transbronchial biopsies do not provide enough tissue for reliable 
diagnosis, the pattern of lung disease in patients with RA for whom treatment for 
pulmonary symptoms is being contemplated is best determined by open-lung biopsy. 
Various histologic patterns have been described, including pulmonary rheumatoid 
nodules, usual interstitial pneumonitis (UIP), bronchiolitis obliterans with patchy 
organizing pneumonia (BOOP), lymphoid hyperplasia, and cellular interstitial infiltrates. 
Patients with rheumatoid nodules, lymphoid hyperplasia, or non-specific cellular 
interstitial infiltrates have a better prognosis than patients with UIP. 
            Pulmonary rheumatoid nodules may occasionally be visualized on routine 
radiographs and confused with malignancy. Occasionally, these nodules may cavitate. 
The unique entity of Caplan’s syndrome defines multiple pulmonary nodules with 
cavitation in coal miners exposed to dust and other inhalants 
.  
Figure 6:a)pulmonary nodule   ;b)caplan syndrome 
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 Cardiac Manifestations: 
             Symptomatic cardiac involvement is rare in patients with RA; however, 
echocardiography has shown the prevalence of asymptomatic cardiac involvement to be 
higher than previously reported in autopsy studies. In a study of patients with RA and no 
cardiac symptoms, there was a significantly increased prevalence of posterior pericardial 
effusion (57.1%), mitral valve prolapse (34.3%), mitral valve thickening (22.9%), aortic 
root dilatation (34.3%), and aortic valve thickening (20.0%) compared to healthy persons.  
                Myocarditis and endocarditis are not commonly seen in patients with RA. 
Areas of focal myocarditis are seen at autopsy but are clinically insignificant. 
Arrhythmias secondary to involvement of the conduction system by myocarditis, 
vasculitis, or nodules can occur but are exceedingly rare. Endocardial disease in the form 
of nonspecific valvulitis has been observed in up to 70% of autopsied cases but is usually 
asymptomatic and generally goes unrecognized during life. Rarely, valvular dysfunction 
may be caused by rheumatoid nodules. Aortitis, most commonly involving the thoracic 
aorta, was identified in 10 of 188 consecutive autopsied cases of patients with RA(8)                     
 Ocular manifestations : 
     The most common ocular manifestations is scleritis ,associated  with anterior uveitis 
or ulcerative keratitis or corneal melt .There is mononuclear infiltrates in the eye leading 
to production of inflammatory cytokines .Ocular  manifestations can predate arthritis 
occurrence and is independent predictor of disease activity.(9) 
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           There is also occurrence of secondary Sjogrens syndrome causing 
keratoconjunctivitis sicca. RF levels correlate with keratoonjunctivitis sicca.  
 
       
DERMATOLOGICAL MANIFESTATIONS: 
          Rheumatoid nodules are the most common specific cutaneous manifestation in 
patients with RA. Rheumatoid papules are an additional characteristic cutaneous 
manifestation associated with RA. The histological features include leukocytoclastic 
vasculitis and palisading granuloma with collagen degeneration. Pyoderma gangrenosum 
can also occur. Rheumatoid vasculitis may at times difficult to diagnose because of the 
                RHEUMATOID SCLERITIS 
Figure 7: ocular manifestations 
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wide variations of clinical presentations. Chronic leg ulcers with or without edema are 
often documented in patients with RA.  (9) 
       The other dermatological manifestations include skin atrophy, transparent skin, 
generalized hyperpigmentation, hyperhidrosis of the patients, erythema nodosum 
,alopecia, vitiligo, urticaria, tylosis, ingrowing  nail (9)
. 
 
Figure 8:a)purpura  
b) atrophic skin with purpura  
c)Methotrexate induced vasculitis 
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        Various nail abnormalities thickening, discoloration, splinter   hemorrhages, 
longitudinal nail beading, curvature abnormalities, and surface abnormalities.  
Hematological manifestations: 
                A mild normocytic normochromic anaemia occurs in patients with rheumatoid 
arthritis .It correlates with elevation of ESR and disease activity. The causes of anaemia 
in RA is mixed.      
                   Thrombocytosis also occurs in RA. There has been a significant correlation 
between thrombocytosis and extra-articular manifestations of RA and disease activity.  
                  Eosinophilia also occurs in some patients .Paraproteinemia is associated with 
poor outcome in rheumatoid arthritis.(10) 
Felty’s Syndrome and Pseudo-Felty’s  Syndrome: 
Felty’s syndrome, which was reported in previous years in as many as 1% of 
patients with RA, was originally described as the association of RA with leukopenia and 
splenomegaly. It was frequently associated with the presence of rheumatoid nodules, 
Sjögren’s disease, and other extra-articular manifestations. (10) 
Felty’s syndrome typically occurred in older patients with advanced erosive RA of 
at least 10 to 20 years’ duration. Almost all Caucasian patients with Felty’s syndrome 
were positive for HLA-DR4. Serum rheumatoid factor is almost always present, usually 
in high titer, and antinuclear antibodies (most commonly antihistone antibodies) are 
present in 47%-100% of patients with Felty’s syndrome.  
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            RA is the disease most frequently associated with the LGL syndrome (up to 39% 
of patients). Patients with the LGL syndrome and RA exhibit idiopathic neutropenia and 
splenomegaly, a condition called pseudo-Felty’s syndrome. Because of an increased 
number of LGLs, the total leukocyte count may be normal in patients with pseudo-Felty’s 
syndrome.(10) 
          Similar to patients with Felty’s syndrome, patients with pseudo-Felty’s syndrome 
have serum rheumatoid factor and other autoantibodies and are susceptible to frequent 
infections. 
 
VASCULITIS:   
            Initially there is an inflammation of medium and small blood vessels. One of the 
most dreaded complication of RA is systemic rheumatoid vasculitis.(11) 
           Risk factors include male gender, long standing disease, high titre RF in serum, 
hypocomplementemia, erosive disease, circulating cryoglobulin, deposition of immune 
complex and complement in blood vessels and extra-articular features such as 
subcutaneous nodules. 
        
The presentations include 
                  1)distal arteritis- splinter hemorrhages ,nail fold infarcts  
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                  2)cutaneous ulceration–pyoderma gangrenosum  
                  3)peripheral neuropathy in the form of mononeuritis multfilex or 
sensoryneuropathy  
 
Figure 9:RA vasculitis 
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Rheumatoid Nodules: 
            Rheumatoid nodules occur in approximately 15% to 40% of patients with RA and 
are associated with the presence of serum rheumatoid factor, erosive joint destruction, 
necrotizing vasculitis, and other extra-articular manifestations of RA. (12) 
            They usually occur in areas that are repeatedly subjected to friction or pressure, 
such as the extensor surface of the forearm or the Achilles tendon; however, nodules may 
also develop in viscera such as the heart and lungs. 
  
Figure:10 –Rheumatoid nodules 
        These nodules are usually smaller than 5 mm and are located on the fingers, 
although they may be present at other sites(12) 
        Histologically, rheumatoid nodules contain a central area of necrosis encircled by 
palisading histiocytes, which are surrounded by granulomatous tissue infiltrated with 
lymphocytes.  
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Malignancy: 
The overall incidence of cancer in patients with RA is not increased; however, 
patients with RA have an increased risk of developing lymphomas and lung cancer, and a 
decreased risk for developing cancers of the colon, rectum, and stomach. The low risk of 
colorectal cancer among RA patients may be related to their common use of nonsteroidal 
anti-inflammatory drugs (NSAIDs).(12) 
          Patients receiving methotrexate therapy for RA have developed non-Hodgkin’s 
lymphoma, which may regress with the discontinuation of methotrexate therapy, as 
occurs with lymphomas in patients receiving immunosuppressive drugs after organ 
transplantation. These reversible lymphomas are usually diffuse, large-cell lymphomas of 
B-cell lineage.(13) 
         Epstein-Barr virus genome and latent membrane protein have been detected in 
lymphomas of patients with RA who were treated with methotrexate alone or with 
cyclosporine A, suggesting that immunosuppression may have contributed to the 
development of these lymphoid neoplasms. (13) 
           Recently, there has been some concern as to whether patients treated with TNF 
inhibitors may be at greater risk of developing lymphomas, particularly non-Hodgkin’s 
lymphoma (NHL). Analysis of any increased risk attributable to therapy is compounded 
by the fact that patients with severe RA are at greater risk of developing NHL than the 
general population, and the risk correlates with the severity and activity of disease. Of  
note, this has been the subset of RA patients for whom TNF inhibitor therapy has been 
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most widely utilized. At present, it seems that much of the increased risk observed among 
patients treated with TNF inhibitors relates to the activity and severity of RA, but this 
bears close observation.(13) 
Prognosis: 
       The clinical expression of RA is usually established in the first 2 years, although the 
disability measures almost always get worse with time. As mentioned previously, 
mortality studies suggest that patients with severe RA die at an accelerated rate due to 
infection, cardiopulmonary disease, and gastrointestinal bleeding. 
         Results from a recent observational study suggest that patients who are 
unresponsive to methotrexate may have a significantly higher mortality risk compared to 
those patients who do respond to methotrexate. The presence of serum rheumatoid factor 
in patients appears to best predict the subsequent development of RA for patients 
presenting with undifferentiated polyarthritis. Patients who have elevated titers of serum 
rheumatoid factor and anti-CCP antibodies early in the course of disease more often 
develop erosive joint disease than patients who are seronegative. High titers of 
rheumatoid factor are also associated with the appearance of extra-articular 
manifestations. Likewise, RA patients who have the HLA-DR4 haplotype usually have a 
poorer clinical outcome.(14) 
           Most patients with RA have a slowly progressive course characterized by 
exacerbations and improvements. Long-term studies have shown that fewer than 10% of 
patients with RA ever go into a prolonged remission. Greater number of tender or 
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swollen joints at disease onset has been correlated with increased disease activity and 
joint erosion. Lower socioeconomic status and fewer years of formal education, which is 
a component of or a surrogate marker for lower socioeconomic status, have been 
associated with higher morbidity and mortality in RA.(14) 
            Defining markers of a bad prognosis early on in RA facilitates therapeutic 
decision-making. Historically, second-line therapy was reserved for severe refractory 
patients who had unremitting disease for years. With recent evidence suggesting that 
erosions appear early, there is a new emphasis on treating RA patients earlier with 
second-line agents. Bad prognostic features include: RF and anti-CCP seropositivity; 
elevated markers of inflammation (ESR and CRP); rheumatoid nodules; extra-articular 
features; larger numbers of active joints; early functional impairment; and early 
appearance of erosions. (15) 
Therapy: 
          Although RA treatment approaches are highly individualized, according to 
practitioner experience and patient preference, several trends deserve mention. 
Controlling pain is a critical objective, but RA with active inflammation needs to be 
differentiated from the mechanical pain that can arise with joint deformity, because 
management strategies will differ.(16) 
         Treatment algorithms should always be used as a guideline to be modified by the 
actual clinical circumstances not as a rigid treatment protocol. The critical step in 
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determining treatment guidelines involves differentiating slowly progressive from 
aggressive disease (16) 
Treatment strategy:  
          A study in early RA from the Netherlands has provided some insight as to the 
relative efficacy of various treatment approaches. In this study, known as the Best trial, 
508 patients with early RA (defined as < 2 years of arthritis) were randomized to one of 4 
treatment arms:  
           1) sequential monotherapy (beginning with methotrexate [MTX]);          
           2) step-up combination therapy (also beginning with MTX);  
           3) initial combination therapy with MTX, sulfasalazine (SSZ) and high dose 
prednisone (as was used in the earlier COBRA study); and 
           4) initial combination therapy with MTX plus TNF-inhibitor (infliximab). In all 
arms, the goal was low levels of disease activity. At their 3 monthly follow up visits, 
patients not achieving this goal, defined by a disease activity score (DAS) of 2.4 or less, 
were required to have their treatment altered according to an algorithm specific for each 
group. Eventually, groups 1, 2, and 3 could end up on MTX plus TNF inhibitor. If 
patients did achieve low disease activity on 2 successive visits, treatment was tapered (to 
a minimum of MTX 10 mg/week over the first 2 years, and off all therapy after the 
second year). Data from the 1 year and 2 years of follow-up showed that patients in 
groups 3 and 4 achieved low disease activity and even remission quicker than did those in 
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groups 1 and 2, although as might have been expected given the study design with its 
mandatory changes in therapies, clinical efficacy was comparable across all groups by 2 
years. (14) 
               However, the progression of joint damage measured radiographically was less 
in groups 3 and 4 through the first 2 years of the study. Preliminary assessment at year 3 
has suggested that a substantial number of patients can have their therapy tapered or even 
discontinued while maintaining low levels of disease activity. This suggests that early 
aggressive therapy may be able to change the course of the disease.(14) 
 
Specific Antirheumatic Drugs: 
NSAIDs and Salicylates: 
   NSAIDs inhibit the production of prostaglandins of the E series, including the 
formation of prostacyclin and thromboxane, resulting in complex effects on vascular 
permeability and platelet aggregation. NSAIDs specifically inhibit cyclooxygenase 
activity and thereby reduce the conversion of arachidonic acid to PGG2.thereby reducing 
pain and swelling. However they do not retard joint destruction. 
Glucocorticoids: 
          Glucocorticoids have profound anti-inflammatory effects caused by the 
suppression of immunomodulating proteins, including IL-1, IL-6, TNF- , interferon-
gamma, and GMCSF. In addition, glucocorticoids inhibit the production and expression 
``33 
 
of pro-inflammatory prostaglandins and leukotrienes, inducible nitric oxide synthase, 
plasminogen activator, and adhesion molecules (ICAM-1). Glucocorticoids  also 
modulate cellular  physiology by reducing  neutrophils at sites of inflammation; 
decreasing the number and function of monocytes ,macrophages (perhaps by affecting 
chemokine physiology); suppressing antigen presenting cells; and inhibiting the number 
of circulating lymphocytes and their functions, including the proliferative response to 
mitogens, cytokine production, and immunoglobulin production. In addition, 
glucocorticoids also produce significant metabolic effects elsewhere. 
Clinical use: Low dosages of glucocorticoids coadministered with NSAIDs and 
DMARDs are used routinely as “bridge therapy” for some patients with very active RA. 
In that setting, the plan is to first quickly extinguish the signs and symptoms of the 
“flare” phenomena, but then to always taper glucocorticoid treatment once the DMARD 
takes effect. In some patients with chronic progressive disease, long-term low-dose 
glucocorticoid treatment is required to maintain the disease at a certain level of control 
and to secure a reasonable quality of life. Glucocorticoids are also used intermittently 
over 1-2 weeks in doses tapering rapidly from 20 mg per day for patients experiencing a 
“flare” of RA. Glucocorticoids  in  high doses is used for treatment of ILD. Intra-articular   
injection of  triamcinolone is used for one or few actively inflamed joints. 
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 Acetaminophen:  
    It has analgesic and antipyretic properties. The exact mechanism of action is 
unknown, but it may have both peripheral and central actions. Acetaminophen is used 
routinely in RA patients to manage pain due to mechanical joint problems. 
DMARDs 
Antimalarial Drugs: 
       These drugs are used in early RA (usually before methotrexate, parenteral gold, and 
anticytokine therapy), or in more aggressive RA as combination chemotherapy with 
methotrexate. A recent controlled trial of hydroxychloroquine showed it to be 
significantly more effective than placebo in patients with early RA. Clinical effects are 
usually observed at 8 to 12 weeks; starting dosage is 400 mg/d in divided doses, with a 
dose reduction to 200 mg/d at 8 to 12 weeks if a good response is observed. 
Sulfasalazine: 
            Sulfasalazine has been used in patients with early mild RA, and long-term studies 
suggest a favorable efficacy profile. Recently, it has also been shown to be marginally 
effective in seronegative spondyloarthropathies, especially among those with psoriatic 
arthritis. But it has little effect on patients with axial spine disease. It is commonly 
prescribed as part of combination therapy with hydroxychloroquine and methotrexate. 
The initial dose is usually 500 mg twice a day, with gradual increase to a total of 3 g/d in 
two divided doses. 
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Methotrexate: 
          It is considered as the gold standard second-line antirheumatic drug against which 
other drugs are usually compared.(17) The newer TNF inhibitors are usually added to 
“partial responders” of methotrexate or after failure with methotrexate or it has caused 
toxicity. 
In RA patients, it may not function as it does in patients with malignancy 
receiving antimetabolite chemotherapy. Evidence suggests inhibition of inflammation as 
a potential mechanism of action. However, methotrexate it will not cause inhibition of 
cyclooxygenase. It causes inhibition of IL-1 and leukotriene-4 (LTB4), and reduces 
levels of proteolytic enzymes(18) 
           It is also useful in the treatment of spondyloarthropathies, systemic vasculitis, and 
nonrenal SLE. But it is most extensively studied in RA patients. In most studies, 
methotrexate induces a predictable response at 6 to 8 weeks, peak occurs at 6 months and 
then it requires progressive increase in dosage of the drug in order to maintain the 
improvement. (18) 
The major side effects include hepatotoxicity. In patients with RA, mild elevation 
of liver enzymes that is transient commonly observed, but cirrhosis, is extremely 
uncommon. (19) 
          Bone marrow suppression causing pancytopenia is an uncommon but clinically 
important adverse event in RA patients on methotrexate therapy. Renal insufficiency 
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resulting in increased drug levels and leading to prolonged exposure to methotrexate may 
cause predisposition to marrow failure(19) 
 Cyclosporine: 
        Cyclosporine causes inhibition of interaction between T-cell and macrophage 
thereby reduces synthesis of IL-2,and prevents IL-1 receptor production, and it 
suppresses the synthesis and release of IL-2 by CD4+cells. Recent studies also show that 
cyclosporine causes increase in insulin–like growth factor levels and bone GLA (gamma-
carboxyglutamic acid) protein and it may cause stimulation of the androgen axis(20). 
Cyclosporine does not inhibit the growth of bone marrow-derived B-lymphocytes, 
myeloid series and erythroid cell lines .(20) 
.         Use of cyclosporin A in rheumatologic conditions has thus far included RA, 
Sjögren’s disease, Behçet’s-related inflammatory eye disease, SLE, scleroderma, 
polymyositis, and systemic vasculitis. Dosages of <5 mg/kg daily reduce potential for 
side effects. A number of combination therapy studies have been reported, among them a 
study comparing the use of cyclosporine A to placebo in RA patients who were 
inadequately controlled with low-dose weekly oral methotrexate. (21)This study showed 
a significant drug effect compared to placebo, although concerns about this continue. 
However, because of the potential for adverse reactions even at the lower doses, 
cyclosporine A use is decreasing as the anti-TNF inhibitors penetrate routine 
practice.(22) 
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Leflunomide: 
        It was initially developed to prevent transplant rejection; it was developed clinically 
for RA patients as an alternative therapy to methotrexate and sulfasalazine. Its active 
metabolite inhibits dihydroorotate dehydrogenase, thereby it interferes with synthesis of 
pyrimidine. (23) In the downstream it causes inhibition of activated T-cells and B- 
lymphocytes and other cells participating in the process of inflammation. It causes 
inhibition of T-cell proliferation and B-cell antibody production. Tyrosine kinase is also 
inhibited by leflunomide .In clinical practice, it use is increased particularly among 
patients who has failed to respond to methotrexate or who were not suitable candidates 
for treatment with anticytokines.(24) 
Tumor Necrosis Factor Inhibitors: 
Etanercept: 
          It is a dimeric fusion protein of the extracellular p75 soluble TNF-alpha receptor 
which is linked to IgG1. Etanercept specifically binds to TNF-alpha and thereby 
preventing its interaction with the TNF-alpha receptor. It is given subcutaneously, at a 
dose of either 25 mg twice per week or at a dose of 50 mg once a week. Similar to all 
TNF inhibitors, it has potential for causing immune suppression and increased risk of 
infection. (25) 
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Infliximab: 
      It is a chimeric IgG1 monoclonal antibody directed against TNF-alpha, thereby it 
causes inhibition of its biologic effects in the synovial tissue. It is given intravenously, 
and following a single intravenous administration of 3 mg/kg, its half-life is 8 to 9.5 days. 
Infliximab has been approved for use, along with methotrexate, at a dose of 3 to 10 
mg/kg given once in 4 to 8 weeks (26). The usually used regimen is 3 mg/kg by 
intravenous infusion at 0, 2, and 6 weeks, followed by 3 mg/kg intravenously every 8 
weeks. Adverse effects include increased bacterial, fungal infections, latent TB 
reactivation, increased risk of lymphoma, drug induced lupus and neurological deficits 
 
Adalimumab: 
       It is a human IgG1 monoclonal antibody directed against TNF-alpha that specifically 
binding circulating and cell-bound TNF, thereby it inhibits its biologic effects. It is given 
subcutaneously and its half-life is approximately 13 days. It is administered at a dose of 
40 mg every alternate week. (27) 
Anakinra: 
           Interleukin-1 (IL-1) which is a pro-inflammatory cytokine that contributes to 
inflammation of the synovial tissue, also by the induction of other inflammatory 
cytokines and induction of protein degrading enzymes such as collagenase. It is a 
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homologue of the naturally occurring antagonist of IL-1 receptor that competes with IL-1 
for binding to type 1 IL-1 receptors. (28) 
            Anakinra is administered as a daily subcutaneous injection. It has a half-life of 
approximately 4-6 hours. It has been found to be effective in several double blind placebo 
controlled trials. In general, responses observed with anakinra is less than that seen with 
TNF inhibitors (28) 
             Infections are important side effects due to active pro-inflammatory nature of IL-
1. In a study in which used anakinra in combination with the TNF inhibitor etanercept, a 
greater number of serious infections developed; therefore, combination therapy is not 
recommended nowadays 
 
Abatacept: 
            It is a T-cell costimulation inhibitor, known as CTLA-4-Ig previously. 
(29)Abatacept is a fusion protein that consists of the extracellular portion of the T-cell 
molecule CTLA-4 connected with human IgG1 Fc portion so that will not activate 
complement. CTLA-4 which is a natural inhibitor of the interaction between CD28, and 
its ligands CD80 and CD86 which is present on antigen presenting cells. It is given as an 
intravenous infusion over a time of 30 minutes once in a month, following an initiation 
treatment phase at weeks 0, 2 and 4. The dose of abatacept is weight based, 
approximately 10 mg/kg. The efficacy of abatacept has been proven in patients with RA 
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with active disease inspite of concurrent MTX or who has failed to respond to previous 
treatment with TNF inhibitors. (29) 
Rituximab:  
              It is a chimeric monoclonal antibody which is directed against CD20, which is 
expressed on B-cells. Thereby causing B-cells depletion thereby leading to reduction of 
inflammatory process. It has been approved for treatment of refractory RA together with 
methotrexate and appears to be more effective in the treatment of seropositive cases when 
compared with seronegative arthritis. Side effects of Rituximab include mild to moderate 
infusion related reactions, infections and risk for development of progressive multifocal 
leukoencephalopathy is very low. (30) 
Tocilizumab: 
             It is a monoclonal antibody directed against IL-6 receptor.IL-6 being a 
proinflammatory cytokine has role in causing inflammation of joints and damage. 
It has been associated with an increased risk of infection, neutropenia, and 
thrombocytopenia (33) 
Tofacitinib:  
          It is a small-molecule inhibitor that primarily inhibits JAK1 and JAK3, which 
mediate signaling of the receptors for the common gamma chain related cytokines1L-
2,IL-4,IL-7,IL-9,IL-15 and IL-21.Tofacitinib in randomized clinical trials has been 
shown to improve the signs and symptoms of RA  significantly over placebo.
  1 
                                            MATERIALS AND METHODS: 
SOURCE OF STUDY: 
          Primary data collected by me from the cases of rheumatoid arthritis attending out -
patient department of Rheumatology at Coimbatore medical college hospital 
DESIGN OF STUDY: Descriptive study 
PERIOD OF STUDY: One year 
METHODOLOGY: 
          This is a descriptive study on the extra -articular manifestations of  RA in 100 
cases of rheumatoid arthritis attending out-patient department or admitted in the medical 
ward of Coimbatore medical college hospital ,Coimbatore from June 2017 to June 
2018.Patients who have been already diagnosed with RA were retrospectively evaluated 
from the hospital records. All these patients were subjected to complete medical history 
and physical examination, complete blood count, urine analysis and blood biochemistry 
by using a well structured pro-forma.The diagnosis of extra-articular manifestations will 
be confirmed by peripheral smear, chest radiography, pulmonary function tests, CT chest, 
ophthalmic examination, ECG, Echocardiography and skin biopsy if skin manifestations 
are present.   The overall frequency of extra-articular manifestations of RA in CMCH  
INCLUSION CRITERIA: 
       The cases fulfilling the American College of  Rheumatism (ACR) and the EULAR 
criteria for rheumatoid arthritis. 
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EXCLUSION CRITERIA: 
1) Patients presenting with polyarthritis but not satisfying the ACR and EULAR 
criteria. 
2) Patients with other systemic illnesses 
3) Patients with other causes of polyarthritis 
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RESULTS: 
TABLE:3 SEX DISTRIBUTION 
 
SEX NO OF PATIENTS PERCENTAGE 
FEMALE 79 79% 
MALE 21 21% 
 
 
CHART:1 
 
 
 
Out of 100 patients with RA,79% were females and 21% were males 
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TABLE 4:AGE DISTRIBUTION: 
 
AGE IN YEARS NO OF PATIENTS PERCENTAGE 
< 30 14 14% 
31-45 37 37% 
46-60 39 39% 
> 60 10 10% 
 
 
CHART 2: 
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 TABLE -5: RA FACTOR 
 
RA FACTOR 
 
NO OF PATIENTS PERCENTAGE 
POSITIVE 
 
80 80% 
NEGATIVE 20 20% 
   
 
CHART 3: 
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TABLE 6:DURATION OF DISEASE 
 
DURATION OF DISEASE NO OF PATIENTS PERCENTAGE 
< 5 YRS 34 34% 
6-10 YRS 17 17% 
11-20 YRS 37 37% 
> 20 YRS 12 12% 
 
In this study, those with duration of disease <5 years were 34%, 
 between 6 and 10 years were 17%,between 11 and 20 years were 37%  and >20 years 
were 12% 
                                      CHART 4:DURATION OF DISEASE 
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              TABLE 7:EXTRA ARTICULAR MANIFESTATIONS 
 
EXTRA ARTICULAR FEATURES NO OF PATIENTS PERCENTAGE 
PRESENT 33 33% 
ABSENT 67 67% 
 
 
CHART: 5 
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TABLE 8:SYSTEM WISE MANIFESTATIONS 
 
EXTRA ARTICULAR MANIFESTATIONS – SYSTEMWISE 
SYSTEM NO OF PATIENTS PERCENTAGE 
HEAMATOLOGICAL 14 42% 
CARDIOLOGICAL 4 12% 
DERMATOLOGICAL 8 24% 
PULMONOLOGICAL 9 27% 
OPHTHALMOLOGICAL 6 18% 
OTHERS 3 10% 
OVERLAP SYNDROMES 2 6% 
                                                      CHART 6: 
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           TABLE 9:EXTRA-ARTICULAR MANIFESTATIONS VS AGE 
 
AGE 
EXTRA ARTICULAR FEATURES 
PRESENT ABSENT 
< 30 0 14 
31-45 7 30 
46-60 19 20 
> 60 7 3 
KRUSAL WALLIS TEST 
P VALUE - 0.001 
SIGNIFICANT 
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TABLE 10:EXTRA-ARTICULAR MANIFESTATIONS VS SEX 
SEX 
EXTRA ARTICULAR FEATURES 
PRESENT ABSENT 
FEMALE 25 54 
MALE 8 13 
CHI SQUARE TEST 
P VALUE - 0.576 
NON SIGNIFICANT 
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 TABLE 11:EXTRA-ARTICULAR FEATURES VS RA FACTOR 
 
RA FACTOR 
EXTRA ARTICULAR FEATURES 
PRESENT ABSENT 
POSITIVE 25 54 
NEGATIVE 8 13 
CHI SQUARE TEST 
P VALUE - 0.576 
NON SIGNIFICANT 
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TABLE 12:EXTRA-ARTICULAR FEATURES VS DURATION OF DISEASE 
DURATION OF DISEASE 
EXTRA ARTICULAR FEATURES 
PRESENT ABSENT 
< 5 YRS 4 30 
6-10 YRS 7 10 
11-20 YRS 12 25 
> 20 YRS 10 2 
KRUSKAL WALLIS TEST 
P VALUE - 0.001 
SIGNIFICANT 
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       TABLE 13: HEMATOLOGICAL FEATURES 
HAEMATOLOGY (N=14) NO OF PATIENTS PERCENTAGE 
ANEAMIA OF CHRONIC DISEASE 6 42.85% 
IRON DEFECIENCY ANEMIA 5 35.71% 
MEGALOBLASTIC ANEMIA 1 7% 
NEUTROPENIA 1 7% 
EOSINOPHILIA 1 7% 
THROMBOCYTOPENIA 1 7% 
THROMBOCYTOSIS 1 7% 
 
CHART 11: 
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TABLE 14: HEMATOLOGICAL FEATURES VS AGE 
AGE 
HAEMATOLOGY FEATURES 
PRESENT ABSENT 
< 30 0 14 
31-45 1 36 
46-60 9 30 
> 60 4 6 
KRUSAL WALLIS TEST 
P VALUE - 0.002 
SIGNIFICANT 
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TABLE 15: HEMATOLOGICAL FEATURES VS SEX 
SEX 
HAEMATOLOGICAL FEATURES 
PRESENT ABSENT 
FEMALE 12 67 
MALE 2 19 
CHI SQUARE TEST 
P VALUE - 0.506 
NON SIGNIFICANT 
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TABLE 16: HEMATOLOGICAL FEATURES VS RA FACTOR 
 
RA FACTOR 
HAEMATOLOGY FEATURES 
PRESENT ABSENT 
POSITIVE 12 68 
NEGATIVE 2 18 
CHI SQUARE TEST 
P VALUE - 0.564 
NON SIGNIFICANT 
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TABLE 17: HEMATOLOGICAL FEATURES VS DURATION OF DISEASE 
DURATION OF DISEASE 
HAEMATOLOGY FEATURES 
PRESENT ABSENT 
< 5 YRS 0 34 
6-10 YRS 2 15 
11-20 YRS 3 34 
> 20 YRS 9 3 
KRUSKAL WALLIS TEST 
P VALUE - 0.001 
SIGNIFICANT 
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TABLE 18: CARDIAC MANIFESTATIONS 
 
CARDIAC MANIFESTATION(N=4) NO OF PATIENTS PERCENTAGE 
CARDIAC FAILURE 1 25.00% 
PAH 2 50.00% 
PERICARDIAL EFFUSION 1 25% 
       
CHART 16: 
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 TABLE 19: CARDIAC MANIFESTATIONS VS AGE 
 
AGE 
CARDIAC MANIFESTATIONS 
PRESENT ABSENT 
< 30 0 14 
31-45 0 37 
46-60 2 37 
> 60 2 8 
KRUSAL WALLIS TEST 
P VALUE - 0.03 
SIGNIFICANT 
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TABLE 20: CARDIAC MANIFESTATIONS VS SEX 
SEX 
CARDIAC MANIFESTATIONS 
PRESENT ABSENT 
FEMALE 4 75 
MALE 0 21 
CHI SQUARE TEST 
P VALUE - 0.293 
NON SIGNIFICANT 
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TABLE 21: CARDIAC MANIFESTATIONS VS RA FACTOR 
RA FACTOR 
CARDIAC MANIFESTATIONS 
PRESENT ABSENT 
POSITIVE 4 76 
NEGATIVE 0 20 
CHI SQUARE TEST 
P VALUE - 0.367 
NON SIGNIFICANT 
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TABLE 22: CARDIAC MANIFESTATIONS VS DURATION OF DISEASE 
DURATION OF DISEASE 
CARDIAC MANIFESTATIONS 
PRESENT ABSENT 
< 5 YRS 0 34 
6-10 YRS 0 17 
11-20 YRS 2 35 
> 20 YRS 2 10 
KRUSKAL WALLIS TEST 
P VALUE - 0.062 
NON SIGNIFICANT 
 
CHART 20: 
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                           TABLE 23: DERMATOLOGICAL FEATURES 
DERMATOLOGY (N=8) 
NO OF 
PATIENTS 
PERCENTAGE 
RHEUMATOID NODULE 1 12.50% 
BILATERAL LEG ULCERS 1 12.50% 
SMALL VESSEL VASCULITIS 1 12.50% 
RAYNAUDS PHENOMENON 1 12.50% 
DIGITAL GANGRENE 1 12.50% 
ATROPHIC SKIN WITH PURPURA 1 12.50% 
PYODERMA GANGRENOSUM 1 12.50% 
 
CHART 21:DERMATOLOGICAL MANIFESTATIONS 
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                                   TABLE 24: SKIN CHANGES VS AGE 
 
AGE 
SKIN CHANGES 
PRESENT ABSENT 
< 30 0 14 
31-45 4 33 
46-60 3 36 
> 60 1 9 
KRUSAL WALLIS TEST 
P VALUE - 0.643 
                                               NON SIGNIFICANT 
  
                                            CHART 22: 
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TABLE 25: SKIN CHANGES VS SEX 
SEX 
SKIN CHANGES 
PRESENT ABSENT 
FEMALE 6 73 
MALE 2 19 
CHI SQUARE TEST 
P VALUE - 0.772 
NON SIGNIFICANT 
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TABLE 26: SKIN CHANGES VS RA FACTOR 
RA FACTOR 
SKIN CHANGES 
PRESENT ABSENT 
POSITIVE 7 73 
NEGATIVE 1 19 
CHI SQUARE TEST 
P VALUE - 0.580 
NON SIGNIFICANT 
 
CHART 24: 
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                       TABLE 27: SKIN CHANGES VS DURATION OF DISEASE 
DURATION OF DISEASE 
SKIN CHANGES 
PRESENT ABSENT 
< 5 YRS 4 30 
6-10 YRS 0 17 
11-20 YRS 4 33 
> 20 YRS 0 12 
KRUSKAL WALLIS TEST 
P VALUE - 0.311 
NON SIGNIFICANT 
 
CHART 25: 
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                                 TABLE 28: PULMONARY MANIFESTATIONS 
PULMONARY MANIFESTATIONS (N = 9) NO OF PATIENTS PERCENTAGE 
INTERSTITIAL LUNG DISEASE 3 33.33% 
RECURENT INFECTIONS 3 33.33% 
PLEURAL EFFUSION 1 11% 
PULMONARY FIBROSIS 1 11% 
RESPIRATORY FAILURE 1 11% 
EOSINOPHILIC PNEUMONIA 1 11% 
 
CHART 26: 
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                TABLE 29: PULMONARY MANIFESTATIONS VS AGE 
AGE 
PULMONARY MANIFESTATIONS 
PRESENT ABSENT 
< 30 0 14 
31-45 1 36 
46-60 5 34 
> 60 3 7 
KRUSAL WALLIS TEST 
P VALUE - 0.026 
SIGNIFICANT 
 
CHART 27: 
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          TABLE 30: PULMONARY MANIFESTATIONS VS SEX 
SEX 
PULMONARY MANIFESTATIONS 
PRESENT ABSENT 
FEMALE 7 72 
MALE 2 19 
CHI SQUARE TEST 
P VALUE - 0.925 
NON SIGNIFICANT 
 
CHART 28: 
 
 
7
7
2
2
1
9
P R E S E N T A B S E N T
L U N G  C H A N G E S
PULMONARY CHANGES VS SEX
FEMALE MALE
71 
 
                TABLE 31: PULMONARY MANIFESTATIONS VS RA FACTOR 
RA FACTOR 
PULMONARY MANIFESTATIONS 
PRESENT ABSENT 
POSITIVE 6 74 
NEGATIVE 3 17 
CHI SQUARE TEST 
P VALUE - 0.295 
NON SIGNIFICANT 
 
TABLE 29: 
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TABLE 32: PULMONARY MANIFESTATIONS VS DURATION OF DISEASE 
DURATION OF DISEASE 
PULMONARY MANIFESTATIONS 
PRESENT ABSENT 
< 5 YRS 0 34 
6-10 YRS 3 14 
11-20 YRS 2 35 
> 20 YRS 4 8 
KRUSKAL WALLIS TEST 
P VALUE - 0.003 
SIGNIFICANT 
 
CHART 30: 
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                         TABLE 33: OPHTHALMOLOGICAL CHANGES 
EYE CHANGES NO OF PATIENTS PERCENTAGE 
DRY EYE 5 83.00% 
EPISCLERITIS 1 17.00% 
 
CHART 31: 
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                                 TABLE 34: EYE CHANGES VS AGE 
AGE 
EYE CHANGES 
PRESENT ABSENT 
< 30 0 14 
31-45 1 36 
46-60 3 36 
> 60 2 8 
KRUSAL WALLIS TEST 
P VALUE - 0.152 
NON SIGNIFICANT 
 
                                                          CHART 32: 
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TABLE 35: EYE CHANGES VS SEX 
 
SEX 
EYE CHANGES 
PRESENT ABSENT 
FEMALE 4 75 
MALE 2 19 
CHI SQUARE TEST 
P VALUE - 0.444 
NON SIGNIFICANT 
 
CHART 33: 
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TABLE 36: EYE CHANGES VS RA FACTOR 
RA FACTOR 
EYE CHANGES 
PRESENT ABSENT 
POSITIVE 5 75 
NEGATIVE 1 19 
CHI SQUARE TEST 
P VALUE - 0.833 
NON SIGNIFICANT 
 
CHART 34: 
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                    TABLE 37: EYE CHANGES VS DURATION OF DISEASE 
DURATION OF DISEASE 
OPHTHALMOLOGICAL 
MANIFESTATIONS 
PRESENT ABSENT 
< 5 YRS 1 33 
6-10 YRS 0 17 
11-20 YRS 3 34 
> 20 YRS 2 10 
KRUSKAL WALLIS TEST 
P VALUE - 0.225 
SIGNIFICANT 
 
CHART : 35 
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                                TABLE 38: OTHER MANIFESTATIONS 
OTHERS NO OF PATIENTS PERCENTAGE 
DISTAL POLYNEUOPATHY 1 33.33% 
MONONEURITIS MULTIPLEX 1 33.33% 
DRUG INDUCED UGI BLEED 1 33% 
  
 
CHART 36: 
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                              TABLE 39: OTHER FEATURES VS AGE 
AGE 
OTHER FEATURES 
PRESENT ABSENT 
< 30 0 14 
31-45 0 37 
46-60 3 36 
> 60 0 10 
KRUSAL WALLIS TEST 
P VALUE - 0.124 
NON SIGNIFICANT 
 
                                               CHART 37 
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TABLE 40: OTHER FEATURES VS SEX 
 
SEX 
OTHER FEATURES 
PRESENT ABSENT 
FEMALE 2 77 
MALE 1 20 
CHI SQUARE TEST 
P VALUE - 0.594 
NON SIGNIFICANT 
 
                                                     CHART 38: 
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                TABLE 41: OTHER FEATURES VS RA FACTOR 
RA FACTOR 
OTHER FEATURES 
PRESENT ABSENT 
POSITIVE 2 78 
NEGATIVE 1 19 
CHI SQUARE TEST 
P VALUE - 0.558 
NON SIGNIFICANT 
 
                                                  CHART 39: 
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                   TABLE 42: OTHER FEATURES VS DURATION OF DISEASE 
DURATION OF DISEASE 
OTHER FEATURES 
PRESENT ABSENT 
< 5 YRS 0 34 
6-10 YRS 0 17 
11-20 YRS 2 35 
> 20 YRS 1 11 
KRUSKAL WALLIS TEST 
P VALUE - 0.323 
NON SIGNIFICANT 
 
                                                      CHART 40: 
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TABLE 43: OVERLAP SYNDROME 
 
OVERLAP SYNDROME NO OF PATIENTS AGE SEX 
SLE OVERLAP 1 40 FEMALE 
SCLERODERMA OVERLAP 1 47 FEMALE 
 
 
OVERLAP SYNDROME DURATION OF DISEASE RA FACTOR 
SLE OVERLAP 6-10 YRS POSITIVE 
SCLERODERMA OVERLAP 6-10 YRS NEGATIVE 
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                                             DISCUSSION 
 
        This study was conducted in Coimbatore medical college hospital from June 2017 to 
June 2018. A total of 100 cases were studied. The clinical and diagnostic findings of this 
study are compared with our studies in literature 
SEX DISTRIBUTION: 
         The ratio of male to female in current study is 1:2.9. 
         In the study done by Turesson C et al, the ratio of male to female patients was 
1:2.71.The sex ratio in this study is comparable to the same in the current study. 
AGE DISTRIBUTION: 
        The age incidence in the current study is 53.66 years 
        In the study done by Maioneet al.,the mean age of the study group was 46.4 
years.the age incidence in this study is lower than the mean age in the current study. 
 RHEUMATOID FACTOR: 
         Pai et al.,Jonssonet al.,Sahatciu-Mekaet al.,Turesson et al., all have found high 
percentage of their cases to be rheumatoid factor positive. All have found rheumatoid 
factor positivity together with higher percentage of extra-articular manifestation. In this 
study 80% of RA patients were sero-positive for RA factor and 20% were 
seronegative.this is comparable to the above quoted study.  
DURATION OF DISEASE: 
        The mean duration of disease in the present study is 11-20years 
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        In the study done by Turesson et al., the mean duration of disease was found to be 
11.8years.this is comparable to the present study. 
 EXTRA-ARTICULAR MANIFESTATIONS: in the study out of 100 patients ,33% of 
RA patient had extra-articular manifestations. 
SYSTEM NO.OF PATIENTS PERCENTAGE 
% 
HAEMETOLOGY 14 42 
CARDIOLOGY 4 12 
DERMATOLOGY 8 24 
PULMONOLOGY 9 27 
OPHTHALMOLOGY 6 18 
OTHERS 3 10 
OVERLAPSYNDROMES 2 6 
 
HEMATOLOGICAL MANIFESTATIONS: 
      In the present study predominant extra-articular manifestation is hematological. The 
most common is anaemia of chronic disease and is present in  42.85% 
    In the study done by Sahatciu-Meka et al.,anaemia was the predominant manifestation 
with 97.8%of the patients having anaemia. this is higher comparable to the present study. 
various haematological manifestations observed in these patients were anaemia of 
chronic disease-42.85%, iron deficiency anaemia-35.71%,megaloblastic anaemia-
7%,neutropenia-7%,eosinophilia-7%,thrombocytopenia-7%, thrombocytosis -7%  
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CARDIAC MANIFESTATIONS: 
     In the present study, cardiac manifestations constitute 12%.the various manifestations 
seen are cardiac failure ,pulmonary artery hypertension and pericardial effusion 
 In the study done by Maione et al. ,cardiac manifestations were seen in 43% of the 
patients which is higher compared to the current study 
OCULAR MANIFESTATIONS: 
      In the present study ,ocular manifestations are found in 18%. ophthalmological 
manifestations observed in this study were dry eyes(83%) and episcleritis(17%) 
 In the study done by Fleming A et al. , episcleritis was observed in 9%of the cases 
scleritis was observed in 4% of cases .In the current study shows higher incidence of 
episcleritis than this study 
DERMATOLOGICAL MANIFESTATIONS : 
            It was present in 8 patients out of 33 which is 24%.and various manifestations 
include methotrexate induced mucositis, rheumatoid nodule, bilateral leg ulcers, small 
vessel vascuitis, raynaud phenomenon, digital gangrene,atrophic skin with purpura and 
pyoderma gangrenosum. 
        In the study done by Sharma et al, vasculitis was present in 2%. In our study 
vasculitis was present in 12.5% which was higher than the study quoted.  
        In our study rheumatoid nodule was found in 12.5%.in the  study done by Sahatciu-
Meka et al., rheumatoid nodules were seen in 12% of the cases. this is comparable to our 
study. 
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        In our study raynaud phenomenon was present in 12.5%.in the study done by 
M.Calguineri et al raynauds was present in 3% of patients which is lesser comparable to 
current study. 
        In the current study purpura was present in 12.5%. In the study done by Sahatciu-
Meka et al.,purpura was observed in 12% of  the cases. This is comparable to current 
study 
PULMONARY MANIFESTATIONS: 
      In the current study pulmonary manifestation was present in 27%.In the study done 
by Sandipan Banik et al pulmonary involvement occur in 33%.this is comparable to the 
current study. In this study pulmonology manifestations were present in 9 patients out of 
33 and it is the second most common extra-articular manifestations of RA.3 had 
interstitial lung disease 3 had recurrent infections. 1 had pleural effusion 1 had pulmonary 
fibrosis 1 had respiratory failure 1 had eosinophilic pneumonia. Those with duration of 
illness more than 20yrs 4 had pulmonological manifestations . 
PERIPHERAL NEUROPATHY 
       In the current study peripheral neuropathy was present in 6%.In the study done  
by Turesson et al peripheral neuropathy is seen in  2.1% of cases. This is lower  
compared to current study. The other manifestations observed in this study include distal 
poly-neuropathy which is present in 1patient and mononeuritis multiplex is present in 1 
patient  
OTHERS 
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      Drug induced UGI bleed is present in 1 patient. 
OVERLAP SYNDROMES 
     ANA was done for these patients and SLE overlap was found in 1 patient. She was 
40yrs female with 6-10 yrs of disease with seropositivity of RF. Scleroderma overlap was 
present in 1 patient. She was 47yrs old female with 6-10yrs of disease with seronegative 
for RA factor   
    The overall presence of majority of extra-articular manifestation is lesser in the present 
study as compared to other studies. This could be attributed to the following reasons: 
    1. The incidence of extra-articular manifestations is much lower in Indian patients as 
evidenced by the Kaushal et al study 
    2. The duration of disease was much lower in this study as compared to other studies. 
    3. The number of cases in the present study is much lower compared to the other 
studies. 
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                                                     Conclusion 
         Extra-articular manifestations were found in 33 cases of rheumatoid arthritis and the 
highest number of patients with EAM were found in the age group of    46-60years 
Male to female ratio was 1:2.9 
    The mean duration of disease was found to be 15.6years with maximum number of 
cases having disease duration between 11 and 20years 
   Anaemia of chronic disease was found to be the most common extra-articular 
manifestation found in this study. The other extra-articular manifestations noted in this 
were cardiac manifestations – 12%; ocular manifestations-18%; dermatological 
manifestation-24% 
Pulmonary manifestation-27%; other-10%;overlap syndromes -6% 
Rheumatoid factor was positive in 80% of patients in this study 
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                                               SUMMARY  
     Rheumatoid arthritis is a chronic inflammatory disease of unknown etiology marked 
by a symmetric peripheral polyarthritis. It is a systemic disease .hence it may result in a 
variety of extra-articular manifestations including fatigue, subcutaneous nodule, lung 
involvement, pericarditis, peripheral neuropathy vasculitis and hematological 
abnormalities. The extra-articular manifestation may develop during the clinical course of 
rheumatoid arthritis even prior to the onset of arthritis. The patient most likely to develop 
extra-articular disease have a history of smoking early onset of significant physical 
disability and seropositivity of rheumatoid factor. 
      Extra-articular manifestations contribute significantly to the morbidity and mortality 
of rheumatoid arthritis. So careful screening of all patients for extra-articular 
manifestations may help reduce the same. 
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ANNEXURE-2 
 
Proforma:     
 
Biodata: Sl no: 
Name: 
Age: 
Sex : 
 
Address: 
Occupation: 
 
ACR/EULAR criteria: 
Score: 
Rheumatoid factor: 
Anti-CCP: 
ESR: 
CRP: 
 
Duration of the disease: 
 
 
Work up for extra-articular 
manifestations: 
 
1.Haematology: 
 Complete hemogram: 
 Peripheral smear: 
 
Hb:            TC:              platelets: 
2.Renal function test: Urea:             creatinine: 
3.Serum electrolytes: Sodium:        Potassium: 
4.Urine rountine:  
5.ECG:  
6.Chest X ray:  
7.Echocardiogram:  
8.USG abdomen&pelvis:  
9.HRCT chest:  
10.Pulmonary function test:  
11.Ophthalmological evaluation:  
12.ANA:  
13.Serum uric acid:  
FINAL DIAGNOSIS:  
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ANNEXURE -3 
 
CONSENT FORM 
 
Yourself Mr./Mrs./Ms………………………………..  are being asked to be a 
participant in the research study titled “A STUDY ON THE EXTRA-ARTICULAR 
MANIFESTATIONS OF RHEUMATOID ARTHRITIS” in CMC Hospital, 
Coimbatore, conducted by DR.PONMOZHI.G M.D., Post Graduate Student, 
Department of General Medicine, Coimbatore Medical College. You are eligible 
after looking into the inclusion criteria. You can ask any question you may have 
before agreeing to participate. 
Research Being Done 
 
A study on the extra-articular manifestations of rheumatoid arthritis 
Purpose of Research 
   To investigate and compare the frequency and type of extra-articular    
manifestations 
   To correlate the number of extra-articular manifestations with the duration of            
the study 
In a well defined community based cohort of patients with rheumatoid arthritis 
       Decline from Participation 
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You have the option to decline from participation in the study existing protocol for 
your condition. 
Privacy and Confidentiality 
Privacy of individuals will be respected and any information about you or provided 
by you during the study will be kept strictly confidential. 
Authorization to publish Results   
Results of the study may be published for scientific purposes and/or presented to 
scientific groups, however you will not be identified.               
 
Statement of Consent 
I volunteer and consent to participate in this study. I have read the consent or it has 
been read to me. The study has been fully explained to me, and I may ask questions 
at any time. 
 
-------------------------------                           -------------------------------   
Signature /Left thumb impression                       Date 
(volunteer)   
--------------------------------                          -------------------------------- 
Signature of witness                                               Date 
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ANNEXURE 4: 
ஒப்புதல் படிவம் 
பெயர ்: 
 
வயது : 
 
ொலினம் : 
 
முகவரி: 
ககாவவ அரசு மருத்துவக்கல்லூரி மருத்துவமவனயில் மருத்துவர ்-
தவலவமயில் நவைபெறும் இந்த ஆய்வில் முழு சம்மதத்துைன் 
கலந்துபகாள்ள சம்மதிக்கிகேன்  .இந்த ஆய்வில் என்வன ெே்றி 
விவரங்கவள ொதுகாெ்புைன் இந்த ஆய்வில்  பவளியிை 
ஆை்கசெவை இல்வல என்று பதரிவித்துக் பகாள்கிகேன்  .எந்த 
கநரத்திலும் ஆய்வில் இருந்து எந்த கநரத்திலும் விலக்கிக்பகாள்ளும்  
உரிவம உை்டு என்று அறிகவன்  . 
இைம் : 
கததி: 
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                                                                                               வகபகயாெ்ெம்  /
கரவக 
 
                                       ANNEXURE  5: MASTER  CHART 
S L 
.NO NAME AGE SEX RF 
DURATION 
OF DISEASE HEMATOLOGY 
CARDIOLOG
Y DERMATOLOGY PULMONOLOGY 
OPHTHALMOLOG
Y OTHER 
OVERLAP 
SYNDROMES 
         
1 Radha Krishnan 56 M + 23years 
anaemia of 
chronic disease - - - - - - 
2 Sangeetha 26 F + 1year - - - - - - - 
3 Janaki 60 F + 28years - - - - - - - 
4 Karuppathal 65 F + 25years 
Anaemia of 
Chronic disease - - - Episcleritis - - 
5 Suganthy 38 F + 12years - - - - - - - 
6 Mangammal 40 F + 14years - - - - - - - 
7 Rangammal 58 F + 14years - - 
Mtxinduced 
mucositis - - - - 
8 Chinnakutty 62 M + 22years - - - - - - - 
9 Sandha 73 F + 38years 
Iron deficiency 
anemia, 
Neutropenia  Cardiac failure - 
Pulmonary fibrosis 
,recurrent 
infections - - - 
10 Rajamani 39 F + 11years - - - - - - - 
11 Krishnaveni 60 F + 23years 
Anemia of 
Chronic disease - - - Dry eye - - 
12 Junaitha 30 F + 5 years - - - - - - - 
13 Vijayalakshmi 47 F - 7years - - - - - - 
SLE 
Overlap 
14 Nagamani 32 F + 2years - - Rheumatoid nodule - - - - 
15 Pangajam 32 F + 8 months - - - - - - - 
16 Shanmugasundaram 45 M - 4 years - - - - - - - 
17 Suseela 36 F + 3years - - - - - - - 
18 Paral 55 F - 22years 
Megaloblastic  
Anaemia - - Pleural nodule - 
Distal 
polyneu
ropathy - 
19 Seethalakshmi 40 F + 3years - - - - - - - 
20 Vasanthi 30 F + 7years - - - - - - - 
21 Kamala 25 F + 3years - - - - - - - 
22 Maragatham 58 F + 20years 
Thrombocytopenia, 
Eosinophilia 
Pulmonary 
artery 
hypertension - ILD - - - 
23 Valarmathi 50 F + 11years - - - - - - - 
24 Chinnaponnu 43 F + 4years - - Bilateral leg ulcers - - - - 
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25 Ponnamal 68 F + 35years 
Megaloblastic  
Anaemia 
Cardiac failure, 
PAH - ILD - - - 
26 Manjula 29 F + 2years - - - - - - - 
27 Loganayaki 40 F + 5years - - - - - - - 
28 Velmurugan 46 M + 16years - - 
Small vessel 
vasculitis - - - - 
29 Pattiyammal 47 F + 12years - - - - - - - 
30 Nivetha 16 F + 1year - - - - - - - 
31 Gowri 49 F - 14years - - - - - - - 
32 Uma maheswari 38 F + 4years - - - - - - - 
33 Maniyammal 45 M + 13years - - - - - - - 
34 Karuppusamy 52 F - 15years - - - Pleural effusion - - - 
35 Maheswari 45 F + 11years - - - - - - - 
36 Nagarathinam 40 F + 6years - - - - - - - 
37 Lakshmi 40 F + 4years - - 
Raynauds 
phenomenon - - - - 
38 Sivagami 46 F + 17years 
Iron deficiency 
anaemia - - - - - - 
39 Abdulla 50 F + 13years - - - - - - - 
40 Maruthayi 51 F + 2oyears 
Iron Ydeficiency 
anaemia, 
Neutropenia - - - - - - 
41 Pushpa 47 F + 7years - - - - - - - 
42 Powjath 44 F + 8years - - - - - - - 
43 Sujatha 32 F - 2years - - - - - - - 
44 Vijaya 45 F + 3years - - Digital gangrene - Dry eye - - 
45 Manimegalai 46 F + 14years - - - - - - - 
46 Vishalani 31 F + 2years - - - - - - - 
47 Arunachalam 58 M + 12years - - - - - - - 
48 Palaniyammal 55 F + 21years 
Anaemia of  
Chronic disease - - - - - - 
49 Bakiyalakshmi 34 F + 3years - - - - - - - 
50 Sumithra 32 F - 2years - - - - - - - 
51 Bakiyam 56 F - 16years - - - - - - - 
52 Paneer selvam 55 M + 11years - - - - Dry eye 
Monone
uritis 
multiple
x - 
53 Selvarani 45 F + 9years - - - - - - - 
54 Velusamy 56 M + 14years - - - - - - - 
55 Ramasamy 64 M + 23years - - - 
ILD,Respiratory 
failure - - - 
56 Gunasundhari 57 F + 17years - 
Pericardial 
effusion - - - - - 
57 Thangavel 65 M + 18years - - - - - - - 
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58 Sekaran 65 M + 12years - - - - - - - 
59 Shantha 45 F + 13years - - - - - - - 
60 Muthulakshmi 45 F - 4years - - - - - - - 
61 Nanjappa 62 M + 12years - - - - Dry eye - - 
62 Rehala 54 F - 8years - - - - - - - 
63 Hemapriya 30 F + 3years - - - - - - - 
64 Velumani 43 M + 11years - - - - - - - 
65 Rangammal 70 F + 20years - - 
Atrophic skin with 
purpura - - - - 
66 Udayakumar 40 M - 3years - - - - - - - 
67 Boopathy 38 M + 8years - - - - - - - 
68 Fowsiya 27 F + 1year - - - - - - - 
69 Brindha 18 F + 1year - - - - - - - 
70 Kavitha 31 F + 4years - - - - - - - 
71 Saroja 44 F + 5years - - - - - - - 
72 Hakim 40 M + 2years - - - - - - - 
73 Suyambukani 51 F + 13years - - 
Pyoderma 
gangrenosum - - - - 
74 Usharani 50 F + 14years - - - - - - - 
75 Shanthi 23 F + 1year - - - - - - - 
76 Vasanthi 30 F - 2years - - - - - - - 
77 Poongodi 54 F + 13years - - - - - 
Drug 
induced 
UGI 
bleeding - 
78 Nagamanikam 30 F + 2years - - - - - - - 
79 Ramasamy 45 M + 11years - - - - - - - 
80 Lakshmi 50 F + 17years 
Anaemia of chronic 
disease, 
Thrombocytosis - - - Dry eye - - 
81 Ambikadevi 38 F + 2years - - - - - - - 
82 Pushpavalli 50 F + 10years - - - - - - - 
83 Prema 32 F - 2years - - - - - - - 
84 Rani 52 F - 10years - - - 
Recurrent 
infections - - - 
85 Dhandapani 75 M - 21years Irondeficiency anaemia - - - - - - 
86 Kuppurakathi 30 F + 2years - - - - - - - 
87 Chinnal 47 F + 12years - - - - - - - 
88 Saroja 60 F + 14years - - - - - - - 
89 Susila 40 F + 9years - - - - - - 
Limited 
scleroderma 
overlap 
90 Rani 45 F + 10years - - - - - - - 
91 Kalaivani 50 F + 8years - - - 
Eosinophilic 
pneumonia, - - - 
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92 Jothimani 52 F + 12years - - - - - - - 
93 Saroja 45 F + 6years 
Irondeficiency  
anaemia - - - - - - 
94 Rajammal 57 F + 8years - - - - - - - 
95 Chandrika 60 F + 12years - - - - - - - 
96 Loganayaki 21 F + 2years - - - - - - - 
97 Supriya 47 F - 13years - - - - - - - 
98 Somasundaram 50 M - 11years - - - - - - - 
99 Rukmani 58 F + 9years 
Anaemia of 
 Chronic disease - - - - - - 
100 Saradha 38 F + 7years - - - 
Recurrent 
infections - - - 
 
 
 
 
 
